Skip to main content

David Nakasone

Head of Investor Relations

Tarsus Pharmaceuticals, Inc. (TARS)

Head of Investor Relations

Ionis Pharmaceuticals Inc (IONS)

Equibles does not estimate personal net worth.

Get an email with a short summary when Tarsus Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.

Get TARS alerts

About David Nakasone

David Nakasone is recorded as Head of Investor Relations at Tarsus Pharmaceuticals, Inc. (TARS) and Head of Investor Relations at Ionis Pharmaceuticals Inc (IONS). David Nakasone has spoken on 9 earnings calls and 1 other investor event across 1 company, most recently for Tarsus Pharmaceuticals, Inc. on May 6, 2026. Tarsus Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Ionis Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Tarsus Pharmaceuticals, Inc. includes Bobak Azamian (CEO and Chairman), Jeffrey S. Farrow (CFO), Leonard Greenstein (CFO) and 7 others.

David Nakasone on recent calls

“Before we begin, I encourage everyone to visit the Investors section of the Tarsus website to be the earnings release and related materials we will be discussing today.”
Head of Investor Relations, Tarsus Pharmaceuticals, Inc. Q1 FY2026 Earnings Call ·
“So we started with about 100-person sales force, and it was really targeted. And about a year into the launch, we added about 50% more, and we knew the size of the market, or roughly 15,000 prescribing eye care professionals, half of them being optometrists and half of them being ophthalmologists.”
Head of Investor Relations, Barclays 28th Annual Global Health Care Conference ·
“Before we begin, I encourage everyone to visit the Investor section of the TARSA's website to see the earnings release and related materials we will be discussing today.”
Head of Investor Relations, Tarsus Pharmaceuticals, Inc. Q4 FY2025 Earnings Call ·
“Before we begin, I encourage everyone to visit the Investors section of the Tarsus website to view the earnings release and related materials we will be discussing today.”
Head of Investor Relations, Tarsus Pharmaceuticals, Inc. Q3 FY2025 Earnings Call ·
“Before we begin, I encourage everyone to visit the Investors section of the Tarsus website to view the earnings release and related materials we will be discussing today.”
Head of Investor Relations, Tarsus Pharmaceuticals, Inc. Q2 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at Tarsus Pharmaceuticals, Inc.

Leadership on record at Ionis Pharmaceuticals Inc

Recent activity